Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2024 05:00 ET | Source: ImCheck Therapeutics SAS

ImCheck obtient 20,18 millions d’euros de financement public dans le cadre du plan France 2030

ImCheck reçoit un financement non-dilutif significatif afin d’accélérer l’avancement de deux programmes innovants, dans le traitement des cancer et des maladies infectieuses, en ligne avec l’ambition...
August 29, 2024 05:00 ET | Source: ImCheck Therapeutics SAS

ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan

FOR IMMEDIATE RELEASE -- ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030...
November 10, 2023 02:30 ET | Source: Capgemini SE

Bpifrance s’associe à Capgemini pour la création de sa Digital Factory de nouvelle génération

Relations presse Capgemini : Hélène Delannet Tel. : + 33 1 57 99 44 51 E-mail : helene.delannet@capgemini.comRelations presse Bpifrance : Juliette FontanillasTel. : +33 6 72 76 08 09 E-mail :...
November 10, 2023 02:30 ET | Source: Capgemini SE

Bpifrance partners with Capgemini for the creation of a next generation digital factory

Media Relations Capgemini: Hélène Delannet Tel.: +33 1 57 99 44 51 E-mail: helene.delannet@capgemini.comMedia Relations Bpifrance: Juliette FontanillasTel.: +33 6 72 76 08 09 E-mail:...
January 05, 2023 02:00 ET | Source: DIACCURATE

Diaccurate est soutenue par Bpifrance pour son Programme DIACC2020 portant sur le développement de nouveaux composés cytotoxiques conjugués à des anticorps thérapeutiques (ADCs)

La plateforme DIACC2020 ambitionne de mettre au point une nouvelle génération de composés cytotoxiques pouvant être conjugués à des anticorps thérapeutiquesElle s’appuie sur les propriétés uniques du...
January 05, 2023 02:00 ET | Source: DIACCURATE

Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)

The DIACC2020 platform aims to develop a new generation of cytotoxic compounds to be conjugated to therapeutic antibodies The Program stems from the unique properties of its proprietary compound...
June 13, 2022 01:00 ET | Source: ImCheck Therapeutics SAS

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...
September 15, 2020 05:00 ET | Source: ImCheck Therapeutics SAS

ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)

ImCheck Announces Investment by BB Pureos Bioventuresto Close Series B Fundraising with Total of €54 million ($64 million) Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced...
August 11, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma obtient un financement public de 6,8M€ pour ses activités de recherche et développement dans la COVID-19

Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce avoir obtenu un financement de 6,8 M€ dans le cadre de l’appel à projet PSCP-COVID...
August 11, 2020 01:00 ET | Source: INNATE PHARMA

Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the Company has obtained funding of €6.8M under the PSPC-COVID call for projects...

Next Page keyboard_arrow_right